News articles about Medtronic PLC (NYSE:MDT) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Medtronic PLC earned a news impact score of 0.19 on Accern’s scale. Accern also gave press coverage about the medical technology company an impact score of 46.472911648912 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news stories that may have effected Accern Sentiment’s rankings:

Medtronic PLC (NYSE MDT) opened at 79.70 on Friday. The firm has a market capitalization of $107.96 billion, a price-to-earnings ratio of 26.83 and a beta of 1.03. Medtronic PLC has a one year low of $69.35 and a one year high of $89.72. The firm’s 50-day moving average is $82.04 and its 200 day moving average is $83.67.

Medtronic PLC (NYSE:MDT) last released its earnings results on Tuesday, August 22nd. The medical technology company reported $1.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.04. The firm had revenue of $7.39 billion during the quarter, compared to analysts’ expectations of $7.44 billion. Medtronic PLC had a net margin of 13.75% and a return on equity of 12.92%. The business’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same period in the prior year, the company earned $1.03 EPS. Analysts forecast that Medtronic PLC will post $4.77 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 29th will be paid a dividend of $0.46 per share. This represents a $1.84 annualized dividend and a yield of 2.31%. The ex-dividend date is Thursday, September 28th. Medtronic PLC’s payout ratio is currently 61.95%.

A number of brokerages have recently commented on MDT. William Blair reissued an “outperform” rating on shares of Medtronic PLC in a research note on Thursday, July 6th. BidaskClub raised shares of Medtronic PLC from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 17th. Wells Fargo & Company reissued an “outperform” rating on shares of Medtronic PLC in a research note on Wednesday, July 12th. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of Medtronic PLC in a research note on Tuesday, July 18th. Finally, BMO Capital Markets raised their target price on shares of Medtronic PLC from $87.00 to $94.00 and gave the company an “outperform” rating in a research note on Tuesday, May 30th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $88.78.

ILLEGAL ACTIVITY WARNING: This story was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at

In related news, EVP Bryan C. Hanson sold 12,000 shares of the company’s stock in a transaction on Monday, July 17th. The shares were sold at an average price of $88.57, for a total transaction of $1,062,840.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Omar Ishrak sold 140,407 shares of the company’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $81.63, for a total transaction of $11,461,423.41. Following the transaction, the chief executive officer now owns 668,503 shares of the company’s stock, valued at $54,569,899.89. The disclosure for this sale can be found here. 0.31% of the stock is owned by corporate insiders.

About Medtronic PLC

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Insider Buying and Selling by Quarter for Medtronic PLC (NYSE:MDT)

Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.